Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp163 | Cushing's | ECE2019

Effects of a single dose of pasireotide on glucose metabolism in patients with Cushing’s disease and predictors of diabetes mellitus developement during treatment

Barbot Mattia , Regazzo Daniela , Zilio Marialuisa , Mondin Alessandro , Lizzul Laura , Pinelli Silvia , Scaroni Carla

Introduction: Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by the high incidence of diabetes mellitus (DM). We aimed to evaluate the effect of a single subcutaneous injection of PAS on glucose metabolism in CD patients, to identify factors predicting rapid deterioration of glycaemic control.Methods: 14 patients [(f/m=12/2, mean age 43±11.3 years, follow-up 17 months (2-63)] with CD treated with ...

ea0049ep1042 | Pituitary - Clinical | ECE2017

Autonomic impairment in idiopathic diabetes insipidus

Barbot Mattia , Ceccato Filippo , Zilio Marialuisa , Albiger Nora , Boscaro Marco , Bilora Franca , Scaroni Carla

Introduction: Since DI was reported to be associated to increase mortality, the aim of this study is to evaluate the presence of autonomic dysfunction (AD) in patients with DI.Methods: We enrolled 12 patients (six females) with central idiopathic DI and 12 controls, matched for age, sex and common cardiovascular risk factors, who were evaluated using the tilt, lying-to-standing, hand grip, deep breath, Valsalva maneuver and Stroop tests.<p class="abs...

ea0037gp.21.01 | Pituitary – Diagnosis of Cushing's disease | ECE2015

A reappraisal of second line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: the role of three dynamic tests

Barbot Mattia , Trementino Laura , Ceccato Filippo , Zilio Marialuisa , Albiger Nora , Boscaro Marco , Arnaldi Giorgio , Scaroni Carla

Introduction: The diagnosis of Cushing’s syndrome (CS) might be challenging especially in ACTH-dependent CS when it comes to detect the origin of ACTH secretion.Materials and methods: We retrospectively recorded data about 170 patients with ACTH-dependent CS (149 CD, 21 EAS) referring to two Endocrinology Units. We focused especially on the performance of 3 dynamic tests: the dexamethasone 8 mg overnight challenging (HDDST), the CRH and the desmopre...

ea0070aep695 | Pituitary and Neuroendocrinology | ECE2020

Markers of recurrence in cushing’s disease: The role of post-operative serum cortisol and desmopressin test

Barbot Mattia , Ceccato Filippo , Lizzul Laura , Mondin Alessandro , Regazzo Daniela , ZIlio Marialuisa , Scaroni Carla

Introduction: Transsphenoidal surgery (TSS) is the first-choice treatment in Cushing’s disease (CD). When performed by experienced neurosurgeon, post-operative remission can be achieved in 70–80% of cases; however, recurrences during follow-up are quite frequent, involving around 20–30% of patients initially in remission. Early detection of relapses is crucial to avoid cortisol-related comorbidities. The aim of the study was to find reliable predictors of rec...

ea0049ep1056 | Pituitary - Clinical | ECE2017

Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing’s disease: an Italian, multicenter study

Albani Adriana , Ferrau Francesco , Messina Erika , Pivonello Rosario , Scaroni Carla , Giordano Carla , Cozzolino Alessia , Zilio Marialuisa , Guarnotta Valentina , Ciresi Alessandro , Iacuaniello Davide , Alibrandi Angela , Colao Annamaria , Cannavo Salvatore

: Patients with Cushing’s disease (CD) have increased cardiovascular risk due to metabolic alterations caused by glucocorticoids excess. Pasireotide, a multireceptor-targeted somatostatin analogue, is a therapeutic option in CD patients in whom surgery is not curative or not feasible. Pasireotide has been shown to be effective in controlling hypercortisolism and to improve metabolic features. Recently, the visceral adiposity index (VAI) has been proposed as a marker of vi...

ea0041ep736 | Neuroendocrinology | ECE2016

The medical treatment with pasireotide in Cushing’s disease: an Italian multicenter experience based on “Real Word Evidence”

Pivonello Rosario , Arnaldi Giorgio , Scaroni Carla Maria , Giordano Carla , Cannavo Salvatore , Iacuaniello Davide , Trementino Laura , Zilio Marialuisa , Guarnotta Valentina , Albani Adriana , Cozzolino Alessia , Michetti Grazia , Boscaro Marco , Colao Annamaria

A recent phase III clinical trial has demonstrated that the treatment with the somatostatin analogue pasireotide normalizes cortisol secretion in 15–28% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the effectiveness of 6-months pasireotide treatment on clinical and hormonal profiles in a group of CD patients with mild to moderate disease according with the real-word evidence. Thirty-two patients with CD unsuccessfully treated ...